Advertisement

Endometrial Effects of SERMs

  • Santiago Palacios

Keywords

Postmenopausal Woman Endometrial Cancer Conjugate Equine Estrogen Healthy Postmenopausal Woman Early Breast Cancer Trialist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Achiron R, Lipitz S, Sivan E, Goldenberg M, Mashiach S (1995) Sonohysterography for ultrasonographic evaluation of tamoxifen-associated cystic thickened endometrium. J Ultrasound Med 14:685–688PubMedGoogle Scholar
  2. 2.
    Achiron R, Grisaru D, Golan-Porat, Lipitz S (1996) Tamoxifen and the uterus: an old drug tested by new modalities. Ultrasound Obstet Gynecol 7:374–378PubMedCrossRefGoogle Scholar
  3. 3.
    Ames BN, Gold LS (1990) Too many rodent carcinogens: mitogenesis increases mutagenesis. Science 249(4972):970–971PubMedGoogle Scholar
  4. 4.
    Andersson M, Storm HH, Mouridsen HT (1991) Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 83:1013–1017PubMedGoogle Scholar
  5. 5.
    Andersson M, Storm HH, Mouridsen HT (1992) Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer. Acta Oncol 31:259–263PubMedGoogle Scholar
  6. 6.
    Ashby J, Odum J, Foster JR (1997) Activity of raloxifene inimmature and ovariectomized rat uterotrophic assays. Regul Toxicol Pharmacol 25(3):226–231PubMedCrossRefGoogle Scholar
  7. 7.
    Berlière M, Charles A, Galant C, Donnez J (1998) Uterine side effects of tamoxifen: a need for systematic pretreatment screening. Obstet Gynecol 91:40–44PubMedCrossRefGoogle Scholar
  8. 8.
    Bese T, Kösebay D, Demirkiran F, Arvas M, Bese N, Mandel N (1996) Ultrasonographic appearence of endometrium in postmenopausal breast cancer patients receiving tamoxifen. Eur J Obstet Gynecol Reprod Biol 67:157–162PubMedCrossRefGoogle Scholar
  9. 9.
    Black LJ, Goode RL (1980) Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY117018) in rats and mice. Life Sci 26(17):1453–1458PubMedCrossRefGoogle Scholar
  10. 10.
    Black LJ, Goode RL (1981) Evidence for biological action of the antiestrogens LY117018 and tamoxifen by different mechanisms. Endocrinology 109(3):987–989PubMedCrossRefGoogle Scholar
  11. 11.
    Black LJ, Jones CD, Falcone JF (1983) Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci 32(9):1031–1036PubMedCrossRefGoogle Scholar
  12. 12.
    Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, et al. (1994) Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93(1):63–69PubMedCrossRefGoogle Scholar
  13. 13.
    Bornstein J, Auslender R, Pascal B, Gutterman E, Isakov D, Abramovici H (1994) Diagnostic pitfalls of ultrasonographic uterine screening in women treated with tamoxifen. J Reprod Med 39:674–678PubMedGoogle Scholar
  14. 14.
    Boss SM, Huster WJ, Neild JA, Glant MD, Eisenhut CC, Draper MW (1997) Effects of raloxifene hydrochloride on the endometriumof postmenopausal women. AmJ Obstet Gynecol 177:1458–1464CrossRefGoogle Scholar
  15. 15.
    Bryant HU, Dere WH (1998) Selective estrogen receptor modulators: an alternative to hormone replacement therapy. Proc Soc Exp Biol Med 217(1):45–52PubMedGoogle Scholar
  16. 16.
    Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389(6652):753–758PubMedCrossRefGoogle Scholar
  17. 17.
    Burke TW, Walker CL (2003) Arzoxifene as therapy for endometrial cancer. Gynecol Oncol 90(2 Pt 2):S40–46PubMedCrossRefGoogle Scholar
  18. 18.
    Cano A, Hermenegildo C (2000) The endometrial effects of SERMs. Hum Reprod Update 6(3):244–254PubMedCrossRefGoogle Scholar
  19. 19.
    Carmichael PL, Mills JJ, Neven P (1998) An epigenetic mechanism for tamoxifen-associated uterine carcinogenesis? Eur J Cancer 34(Suppl 4):S10–S11CrossRefGoogle Scholar
  20. 20.
    Carthew P, Edwards RE, Nolan BM (1999)Uterotrophic effects of tamoxifen, toremifene, and raloxifene do not predict endometrial cell proliferation in the ovariectomized CD1 mouse. Toxicol Appl Pharmacol 158(1):24–32PubMedCrossRefGoogle Scholar
  21. 21.
    Cauley JA, Norton L Lippman ME, Eckert S, Krueger KA, Purdie DW, et al. (2001) Continued breast cancer risk reduction in postmenopasusal women treated with raloxifene: 4 year results from the MORE trial. Breast Cancer Res Treatment 65:125–134CrossRefGoogle Scholar
  22. 22.
    Christodoulacos G, Panoulis C, Botsis D, Rizoz D, Kassanos D, Creatsas G (2002) Transvaginal sonographic monitoring of the uterine effects of raloxifene and a continuous combined replacement therapy in postmenopausal women. Maturitas 42:77–84PubMedCrossRefGoogle Scholar
  23. 23.
    Clark ER, Jordan VC (1976) Oestrogenic, anti-oestrogenic and fertility effects of some triphenylethanes and triphenylethylenes related to ethamoxytriphetol (MER 25). Br J Pharmacol 57(4):487–493PubMedGoogle Scholar
  24. 24.
    Cohen I, Rosen DJ, Shapira J, Cordoba M, Gilboa S, Altaras MM, et al. (1994) Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients. Gynecol Oncol 52:185–190PubMedCrossRefGoogle Scholar
  25. 25.
    Cohen FJ, Watts S, Shah A, Akers S, Plouffe L (2000) Uterine effects of 3-years raloxifene therapy in postmenopausal women younger than age 60. Obstet Gynecol 95(1):104–111PubMedCrossRefGoogle Scholar
  26. 26.
    Colletta AA, Wakefield LM, Howell FV, van Roozendaal KE, Danielpour D, Ebbs SR, Sporn MB, Baum M (1990) Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer 62(3):405–409PubMedGoogle Scholar
  27. 27.
    Cook LS, Weiss NS, Schwartz SM, White E, McKnight B, Moore DE, et al. (1995) Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst 87:1359–1364PubMedGoogle Scholar
  28. 28.
    Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. (1999) The effect of raloxzifene on risk of breast cancer in postmenopausal women:results from MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. J Am Med Assoc 281:2189–2197CrossRefGoogle Scholar
  29. 29.
    Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641–1647PubMedCrossRefGoogle Scholar
  30. 30.
    De Muylder X, Neven P, De Somer M, Van Belle Y, Vanderick G, De Muylder E (1991) Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynaecol Obstet 36:127–130PubMedCrossRefGoogle Scholar
  31. 31.
    Dijkhuizen FP, Brölmann HA, Potters AE, Bongers MY, Heintz AP (1996) The accuracy of transvaginal ultrasonography in the diagnosis of endometrial abnormalities. Obstet Gynecol 87:345–349PubMedCrossRefGoogle Scholar
  32. 32.
    Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C (1996) Acontrolled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 11:835–842PubMedCrossRefGoogle Scholar
  33. 33.
    Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351(9114):1451–1467CrossRefGoogle Scholar
  34. 34.
    Elkas J, Gray K, Howard L, Petit N, Pohl J, Armstrong A (1998) The effects of tamoxifen on endometrial insulin-like growth factor-1 expression. Obstet Gynecol 91(1):45–50PubMedCrossRefGoogle Scholar
  35. 35.
    Fisher B (1996) A commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients. J Clin Oncol 14:1027–1039PubMedGoogle Scholar
  36. 36.
    Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320(8):479–484PubMedCrossRefGoogle Scholar
  37. 37.
    Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14). J Natl Cancer Inst 86:527–537PubMedGoogle Scholar
  38. 38.
    Fisher B, Costantino JP, Wickerham L, Redmond CK, Kavanah M, Cronin WM, et al. (1998) Tamoxifen for prevention of brest cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388PubMedCrossRefGoogle Scholar
  39. 39.
    Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfversward C, et al. (1989) Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1(8630):117–120PubMedCrossRefGoogle Scholar
  40. 40.
    Fugere P, Scheele WH, Shah A, et al. (2000) Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in postmenopausal women. Am J Obstet Gynecol 182:568–574PubMedCrossRefGoogle Scholar
  41. 41.
    Gal D, Kopel S, Basheukin M, Lebowicz J, Lev R, Tancer L (1991) Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer. Preliminary report. Gynecol Oncol 42:120–123PubMedCrossRefGoogle Scholar
  42. 42.
    Gottardis MM, Ricchio ME, Satyaswaroop PG, Jordan VC (1990) Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. Cancer Res 50(11):3189–3192PubMedGoogle Scholar
  43. 43.
    Granberg S, Wikland M, Karlsson B, Norström A, Friberg L (1991) Endometrial thickness as measured by endovaginal ultrasonography for identifying endometrial abnormality. Am J Obstet Gynecol 164:47–52PubMedGoogle Scholar
  44. 44.
    Grese TA, Sluka JP, Bryant HU, Cullinan GJ, Glasebrook AL, Jones CD, Matsumoto K, Palkowitz AD, Sato M, Termine JD, Winter MA, Yang NN, Dodge JA (1997) Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci USA 94(25):14105–14110PubMedCrossRefGoogle Scholar
  45. 45.
    Holbert TR (1997) Transvaginal ultrasonographic measurement of endometrial thickness in postmenopausal women receiving estrogen replacement therapy. Am J Obstet Gynecol 176:1334–1339PubMedCrossRefGoogle Scholar
  46. 46.
    Huynh HT, Pollak M (1993) Insulin-like growth factor I gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780. Cancer Res 53(23):5585–5588PubMedGoogle Scholar
  47. 47.
    Huynh H, Pollak M (1994) Uterotrophic actions of estradiol and tamoxifen are associated with inhibition of uterine insulin-like growth factor binding protein 3 gene expression. Cancer Res 54(12):3115–3119PubMedGoogle Scholar
  48. 48.
    Isaksson E, Cline JM, Skoog L, Soderqvist G, Wilking N, von Schoultz E, von Schoultz B (1999) p53 expression in breast and endometrium during estrogen and tamoxifen treatment of surgically postmenopausal cynomolgus macaques. Breast Cancer Res Treat 53(1):61–67PubMedCrossRefGoogle Scholar
  49. 49.
    Jolly EE, Bjarnason NH, Neven P, Plouffe L Jr, Johnston CC Jr, Watts SD, Arnaud CD, Mason TM, Crans G, Akers R, Draper MW (2003) Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 10(4):337–344PubMedCrossRefGoogle Scholar
  50. 50.
    Jordan VC, Glusman JE, Eckert S, Lippman M, Powles T, Costa A, et al. (1998) Incident primary breast cancer are reduced by raloxifen: integrated data from multicenter, double-blind, randomized trial in≈ 12,000 postmenopausal women. Proc Am Soc Clin Oncol 17:122a (abstract)Google Scholar
  51. 51.
    Karlsson S, Iatropoulos MJ, Williams GM, Kangas L, Nieminen L(1998) Theproliferation in uterine compartments of intact rats of two different strains exposed to high doses of tamoxifen or toremifene. Toxicol Pathol 26(6):759–768PubMedCrossRefGoogle Scholar
  52. 52.
    Ke HZ, Foley GL, Simmons HA, Shen V, Thompson DD (2004) Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology 145(4):1996–2005PubMedCrossRefGoogle Scholar
  53. 53.
    Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, et al. (1994) Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 343:1318–1321PubMedCrossRefGoogle Scholar
  54. 54.
    Kleinman D, Karas M, Danilenko M, Arbell A, Roberts CT, LeRoith D, Levy J, Sharoni Y (1996) Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor (IGF)-I induced tyrosine phosphorylation and reduction in IGF binding proteins. Endocrinology 137(3):1089–1095PubMedCrossRefGoogle Scholar
  55. 55.
    Koda M, Jarzabek K, Haczynski J, Knapp P, Sulkowski S, Wolczynski S (2004) Differential effects of raloxifene and tamoxifen on the expression of estrogen receptors and antigen Ki-67 in human endometrial adenocarcinoma cell line. Oncol Rep 12(3):517–521PubMedGoogle Scholar
  56. 56.
    Kommoss F, Karck U, Prompeler H, Pfisterer J, Kirkpatrick CJ (1998) Steroid receptor expression in endometria from women treated with tamoxifen. Gynecol Oncol 70(2):188–191PubMedCrossRefGoogle Scholar
  57. 57.
    Ma L, Palkowitz A, Bryant HU, Rowley E, Adian MD, Cole HW, Shetler P, Smith S, Turner CH, Yao W, et al. (1998) Long-term dosing of LY353381HC1 preserves bone quality, reduces turnover and lowers cholesterol levels in ovariectomized rats. Bone 23(Suppl 5):S609Google Scholar
  58. 58.
    MacGregor JI, Jordan VC (1998) Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 50(2):151–196PubMedGoogle Scholar
  59. 59.
    Maeda T, Ke HZ, Simmons H, Thompson D (2004) Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies. Clin Calcium 14(10):85–93PubMedGoogle Scholar
  60. 60.
    Magriples U, Naftolin F, Schartz PC, Carcangiu ML (1993) High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 11:485–490PubMedGoogle Scholar
  61. 61.
    McGonigle KF, Shaw SL, Vasilev SA, Odom-Maryon T, Roy S, Simpson JF (1998) Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy. Am J Obstet Gynecol 178:1145–1150PubMedCrossRefGoogle Scholar
  62. 62.
    Miller CP, Collini MD, Tran BD (2001) Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens. J Med Chem. 44:1654–1657PubMedCrossRefGoogle Scholar
  63. 63.
    Miller CP, Harris HA, Konmin BS (2002) Bezedoxifene Acetate. Drugs Future 27(2):117–121CrossRefGoogle Scholar
  64. 64.
    Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS (1991) Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 83:1450–1459PubMedGoogle Scholar
  65. 65.
    Neven P, De Muylder X, Van Belle Y, Vanderick G, De Muylder E (1990) Hysteroscopic follow-up during tamoxifen treatment. Eur J Obstet Gynecol Reprod Biol 35:235–238PubMedCrossRefGoogle Scholar
  66. 66.
    Neven P, Lunde T, Benedetti-Panicini P, et al. (2000) A multicentre randomized trial to compare the uterine effects of raloxifene(evista) with a continuous combined hormone replacement therapy (kliogest); results from Euralox I. Gynecol Endocrinol 14(2):77Google Scholar
  67. 67.
    Neven P, Lunde T, Benedetti-Panici P, Tiitinen A, Marinescu B, Villiers T, Hillard T, Cano A, Peer E, Quail D, Nickelsen T (2003) Amulticentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate. Br J Obstet Gynaecol 110:157–167Google Scholar
  68. 68.
    Neven P, Quail D, Levrier M, Aguas F, The HS, De Geyter C, Glant MD, Beck H, Bosio-LeGoux B, Schmitt H, Hottgenroth A, Nickelsen T (2004) Uterine effects of estrogen plus progestin therapy and raloxifene: adjudicated results from the EURALOX study. Obstet Gynecol 103(5 Pt 1):881–891PubMedGoogle Scholar
  69. 69.
    Palacios S, Cifuentes I, Menendez C, von Helde S (2000) Los SERMs y el utero. In: Cano A, Calaf J (eds) Moduladores selectivos de los receptores de estrogenos (SERM). Ediciones Doyma, BarcelonaGoogle Scholar
  70. 70.
    Rivera-Gonzalez R, Petersen DN, Tkalcevic G, Thompson DD, Brown TA (1998) Estrogen-induced genes in the uterus of ovariectomized rats and their regulation by droloxifene and tamoxifen. J Steroid Biochem Mol Biol 64(1–2):13–24PubMedCrossRefGoogle Scholar
  71. 71.
    Robertson JA, Bhattacharyya S, Ing NH (1998) Tamoxifen up-regulates oestrogen receptor-alpha, c-fos and glyceraldehyde 3-phosphate-dehydrogenase mRNAs in ovine endometrium. J Steroid Biochem Mol Biol 67(4):285–292PubMedCrossRefGoogle Scholar
  72. 72.
    Rose PG (1996) Endometrial carcinoma. N Engl J Med 335:640–649PubMedCrossRefGoogle Scholar
  73. 73.
    Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR, van Zwieten MJ (1990) Comparative study of human and rat mammary tumorigenesis. Lab Invest 62(3):244–278PubMedGoogle Scholar
  74. 74.
    Rutanen EM, Heikkinen J, Halonen K, Komi J, Lammintausta R, Ylikorkala O (2003) Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial. Menopause 10(5):433–439PubMedCrossRefGoogle Scholar
  75. 75.
    Sasco AJ, Raffi F, Satge D, Goburdhun J, Fallou HB, Leduc B (1995) Endometrialmüllerian carcinosarcoma after cessation of tamoxifen therapy for breast cancer. Int J Gynaecol Obstet 48:307–310PubMedCrossRefGoogle Scholar
  76. 76.
    Sato M, Rippy MK, Bryant HU (1996) Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J 10(8):905–912PubMedGoogle Scholar
  77. 77.
    Sato M, Zeng GQ, Rowley E, Turner CH (1998) LY353381 × HCl: an improved benzothiophene analog with bone efficacy complementary to parathyroid hormone-(1–34). Endocrinology 139(11):4642–4651PubMedCrossRefGoogle Scholar
  78. 78.
    Somjen D, Waisman A, Kaye AM (1996) Tissue selective action of tamoxifen methiodide, raloxifene and tamoxifen on creatine kinase B activity in vitro and in vivo. J Steroid Biochem Mol Biol 59(5–6):389–396PubMedCrossRefGoogle Scholar
  79. 79.
    Stewart HJ, Knigth GM (1989) Tamoxifen and the uterus and endometrium. Lancet 1:375–376PubMedGoogle Scholar
  80. 80.
    Swenberg JA (1997) Clinical relevance of laboratory and animal data on tamoxifen. Oncology (Huntingt) 11(2 Suppl 1):39–44PubMedGoogle Scholar
  81. 81.
    Swerdlow AJ, Jones ME, British Tamoxifen Second Cancer Study Group (2005) Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst 97(5):375–384PubMedCrossRefGoogle Scholar
  82. 82.
    Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, McDonnell DP (1994) Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 8(1):21–30PubMedCrossRefGoogle Scholar
  83. 83.
    van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrère CH, Otter R, et al. (1994) Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343:448–452PubMedCrossRefGoogle Scholar
  84. 84.
    Voipio SK, Komi J, Kangas L, Halonen K, DeGregorio MW, Erkkola RU (2002) Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women. Maturitas 43(3):207–214PubMedCrossRefGoogle Scholar
  85. 85.
    Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, et al. (1998) Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. J Am Med Assoc 279:1445–1451CrossRefGoogle Scholar
  86. 86.
    Zhang H, McElrath T, Tong W, Pollard JW (2005) The molecular basis of tamoxifen induction of mouse uterine epithelial cell proliferation. J Endocrinol 184(1):129–140PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2006

Authors and Affiliations

  • Santiago Palacios
    • 1
  1. 1.Institute Palacios of Woman’s HealthMadridSpain

Personalised recommendations